For research use only. Not for therapeutic Use.
RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely[1].
RP101988 is a substrate of P-gp and breast cancer resistance protein (BCRP) drug transporters[2].
| Catalog Number | I045824 |
| CAS Number | 2990018-57-8 |
| Synonyms | 2-[[(1S)-4-[5-(3-cyano-4-propan-2-yloxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-inden-1-yl]amino]acetic acid |
| Molecular Formula | C23H22N4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H22N4O4/c1-13(2)30-20-9-6-14(10-15(20)11-24)23-26-22(27-31-23)18-5-3-4-17-16(18)7-8-19(17)25-12-21(28)29/h3-6,9-10,13,19,25H,7-8,12H2,1-2H3,(H,28,29)/t19-/m0/s1 |
| InChIKey | HICWSCLKDYAXPD-IBGZPJMESA-N |
| SMILES | CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCC(=O)O)C#N |
| Reference | [1]. Tran JQ, et al. Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study. Clin Pharmacol Drug Dev. 2018;7(3):263-276. [2]. Gilardi D, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD [published online ahead of print, 2020 Jul 1]. Expert Rev Gastroenterol Hepatol. 2020;1-10. |
